ACADIA Pharmaceuticals (ACAD) Competitors $19.95 -0.34 (-1.68%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$19.32 -0.63 (-3.13%) As of 02/21/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ACAD vs. VTRS, MRNA, RDY, PCVX, SRPT, QGEN, ASND, ROIV, RVMD, and LEGNShould you be buying ACADIA Pharmaceuticals stock or one of its competitors? The main competitors of ACADIA Pharmaceuticals include Viatris (VTRS), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), Sarepta Therapeutics (SRPT), Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry. ACADIA Pharmaceuticals vs. Viatris Moderna Dr. Reddy's Laboratories Vaxcyte Sarepta Therapeutics Qiagen Ascendis Pharma A/S Roivant Sciences Revolution Medicines Legend Biotech Viatris (NASDAQ:VTRS) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, community ranking, media sentiment and institutional ownership. Which has more volatility & risk, VTRS or ACAD? Viatris has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500. Which has better valuation & earnings, VTRS or ACAD? Viatris has higher revenue and earnings than ACADIA Pharmaceuticals. Viatris is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViatris$15.05B0.89$54.70M-$0.74-15.20ACADIA Pharmaceuticals$726.44M4.57-$61.29M$0.7825.58 Do insiders & institutionals believe in VTRS or ACAD? 79.9% of Viatris shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 0.1% of Viatris shares are owned by insiders. Comparatively, 28.3% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media refer more to VTRS or ACAD? In the previous week, ACADIA Pharmaceuticals had 4 more articles in the media than Viatris. MarketBeat recorded 6 mentions for ACADIA Pharmaceuticals and 2 mentions for Viatris. ACADIA Pharmaceuticals' average media sentiment score of 0.74 beat Viatris' score of -0.20 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ACADIA Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is VTRS or ACAD more profitable? ACADIA Pharmaceuticals has a net margin of 13.83% compared to Viatris' net margin of -5.87%. ACADIA Pharmaceuticals' return on equity of 25.83% beat Viatris' return on equity.Company Net Margins Return on Equity Return on Assets Viatris-5.87% 16.46% 7.09% ACADIA Pharmaceuticals 13.83%25.83%14.71% Does the MarketBeat Community favor VTRS or ACAD? ACADIA Pharmaceuticals received 871 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 73.08% of users gave ACADIA Pharmaceuticals an outperform vote while only 35.48% of users gave Viatris an outperform vote. CompanyUnderperformOutperformViatrisOutperform Votes2235.48% Underperform Votes4064.52% ACADIA PharmaceuticalsOutperform Votes89373.08% Underperform Votes32926.92% Do analysts rate VTRS or ACAD? Viatris presently has a consensus price target of $13.67, suggesting a potential upside of 21.48%. ACADIA Pharmaceuticals has a consensus price target of $24.00, suggesting a potential upside of 20.30%. Given Viatris' higher probable upside, research analysts plainly believe Viatris is more favorable than ACADIA Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viatris 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00ACADIA Pharmaceuticals 0 Sell rating(s) 8 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.53 SummaryACADIA Pharmaceuticals beats Viatris on 14 of the 18 factors compared between the two stocks. Get ACADIA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACAD vs. The Competition Export to ExcelMetricACADIA PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.32B$7.04B$5.77B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E Ratio25.586.1326.4618.82Price / Sales4.57313.76455.0280.40Price / CashN/A67.8344.0437.47Price / Book7.596.747.634.64Net Income-$61.29M$138.11M$3.18B$245.69M7 Day Performance-0.45%-2.43%-1.91%-2.66%1 Month Performance12.02%-1.91%-0.19%-2.15%1 Year Performance-19.72%-5.03%16.70%12.90% ACADIA Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACADACADIA Pharmaceuticals2.901 of 5 stars$19.95-1.7%$24.00+20.3%-19.8%$3.32B$726.44M25.58510Upcoming EarningsShort Interest ↓VTRSViatris2.3258 of 5 stars$10.80flat$13.67+26.5%-15.2%$12.89B$15.43B-14.5938,000News CoverageMRNAModerna4.7346 of 5 stars$32.99+3.4%$66.89+102.8%-59.4%$12.70B$6.85B-5.675,600Analyst DowngradeOptions VolumeHigh Trading VolumeRDYDr. Reddy's Laboratories2.8657 of 5 stars$13.60-2.8%$17.00+25.0%-11.9%$11.35B$311.31B21.6527,048PCVXVaxcyte2.5871 of 5 stars$84.00+0.2%$127.71+52.0%+10.4%$10.47BN/A-18.26160Insider TradePositive NewsSRPTSarepta Therapeutics4.4948 of 5 stars$107.95-1.4%$176.77+63.8%-19.7%$10.31B$1.24B86.361,314Upcoming EarningsQGENQiagen4.4259 of 5 stars$39.85-0.5%$48.78+22.4%-5.2%$8.84B$1.98B110.975,967Analyst DowngradeASNDAscendis Pharma A/S3.1724 of 5 stars$144.08+1.1%$193.43+34.3%-3.0%$8.74B$288.08M-17.83640Analyst ForecastROIVRoivant Sciences2.5635 of 5 stars$10.56+1.1%$18.08+71.2%-7.5%$7.69B$122.59M1.87860Insider TradeRVMDRevolution Medicines4.5103 of 5 stars$40.67-1.6%$66.25+62.9%+41.7%$6.84B$11.58M-11.33250LEGNLegend Biotech2.594 of 5 stars$36.42+0.1%$79.50+118.3%-33.7%$6.65B$285.14M-38.341,800News CoveragePositive NewsGap Up Related Companies and Tools Related Companies Viatris Alternatives Moderna Alternatives Dr. Reddy's Laboratories Alternatives Vaxcyte Alternatives Sarepta Therapeutics Alternatives Qiagen Alternatives Ascendis Pharma A/S Alternatives Roivant Sciences Alternatives Revolution Medicines Alternatives Legend Biotech Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACAD) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ACADIA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
